<DOC>
	<DOCNO>NCT00202787</DOCNO>
	<brief_summary>The purpose study determine confirm objective response rate combination therapy cetuximab FOLFOX4 FOLFOX4 alone patient CRC non-resectable hepatic metastasis</brief_summary>
	<brief_title>Safety Efficacy Study Combination Therapy With Cetuximab FOLFOX4 Patients With Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Written inform consent . Men woman &lt; 75 year Histologically confirm diagnosis CRC Metastatic colorectal carcinoma exclusive nonresectable hepatic metastasis , due fulfillment one follow criterion : 1 . Number hepatic metastasis &gt; or= 4 ; 2 . Size one hepatic metastasis &gt; 5 cm diameter ; 3 . Vascular involvement and/or poor site prevent complete resection hepatic disease and/or require resection remain liver mass less 2530 % functional liver . Presence least one lesion detectable twodimensional measurement . Karnofsky functional status &gt; or=70 % time enrollment study Life expectancy great 3 month . Patients must receive chemotherapy advanced/metastatic disease . Patients follow characteristic enrol : 1 . Recurrence adjuvant treatment 5fluorouracil/folinic acid capecitabine +/ radiotherapy diseasefree period &gt; 6 month follow conclusion treatment . 2 . Recurrence surgical and/or radiotherapy treatment without adjuvant systemic treatment . 3 . De novo diagnosis disease . Proper liver function , define aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; = 2.5 x ULN ( &lt; = 5 x ULN hepatic metastasis ) total bilirubin count &lt; 1.5 x ULN . Proper kidney function , define serum creatinine &lt; 1.5 x ULN . Proper hematological function , define neutrophil count &gt; = 1.5 x 109/l , platelet &gt; = 100 X 109/l hemoglobin &gt; = 9 g/dl . Effective birth control method men well woman possibility pregnancy Documented suspect cerebral and/or leptomeningeal metastasis . Metastasis nonhepatic site , include extrahepatic lymph node metastasis . Surgery ( exclude biopsy diagnosis ) and/or radiotherapy within 4 week prior enrollment study . Participation another clinical trial medication past 30 day . Chronic , concomitant administration systemic immunotherapy , chemotherapy , hormone therapy investigational drug . Prior malignant tumour past 5 year , except history basal cell skin carcinoma preinvasive cervical carcinoma . Any investigational drug 4 week prior enrolment . Prior administration monoclonal antibody , EGFR signal transduction inhibitor EGFRtargeted treatment . Prior participation study treatment cetuximab assign ( whether treatment cetuximab receive ) Acute subacute intestinal occlusion history inflammatory intestinal disease . Evidence grade 3 4 allergic reaction treatment component . Clinically relevant peripheral neuropathy . Clinically relevant myocardial disease history myocardial infarction past 12 month . Known abuse alcohol / drug , Legal incapacity limit legal capacity . Any medical psychological disorder , opinion investigator , allow patient conclude study sign inform consent . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>cetuximab</keyword>
	<keyword>FOLFOX4</keyword>
</DOC>